Professor Thomas Phillips' Outputs (3)

Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group (2023)
Journal Article
Parker, R., Allison, M., Anderson, S., Aspinall, R., Bardell, S., Bains, V., …Masson, S. (2023). Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group. BMJ Open Gastroenterology, 10(1), Article e001221. https://doi.org/10.1136/bmjgast-2023-001221

Objective Alcohol-related liver disease (ALD) is the most common cause of liver-related ill health and liver-related deaths in the UK, and deaths from ALD have doubled in the last decade. The management of ALD requires treatment of both liver disease... Read More about Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group.

Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT (2023)
Journal Article
Donoghue, K., Boniface, S., Brobbin, E., Byford, S., Coleman, R., Coulton, S., …Drummond, C. (2023). Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT. Health Technology Assessment, 27(22), 1-88. https://doi.org/10.3310/DQKL6124

Background: Acamprosate is an effective and cost-effective medication for alcohol relapse prevention but poor adherence can limit its full benefit. Effective interventions to support adherence to acamprosate are therefore needed. Objectives: To deter... Read More about Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT.

Telemedicine in addictions: Feasibility randomised controlled trial (2023)
Journal Article
Mayet, S., Gledhill, A., McCaw, I., Hashmani, Z., Drozdova, Z., Arshad, S., Shahbaz, S., Huang, C., & Phillips, T. (2023). Telemedicine in addictions: Feasibility randomised controlled trial. Heroin Addiction and Related Clinical Problems, 25(3), 27-36

Background. Opioid dependence is high risk. Opioid agonist treatment (OAT) improves outcomes and reduces deaths. Nonattendance at addiction specialist prescribers who monitor OAT worsens outcomes. Telemedicine has been shown to improve attendance wit... Read More about Telemedicine in addictions: Feasibility randomised controlled trial.